<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8119.21675 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/25/2022 8:02:32 PM -->
      <!-- iXBRL Library version: 1.0.8119.21683 -->
      <!-- iXBRL Service Job ID: 31116083-be22-4d71-ac79-54d24c938b33 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrns="http://marinus.com/20220523" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:EntityCentralIndexKey" id="Tc_fQwut4DMhUWj8XJJstzLhg_2_1">0001267813</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:AmendmentFlag" id="Tc_4f8yb0l4O0--wxGvPVSNeg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="mrns-20220523.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-23</xbrli:startDate><xbrli:endDate>2022-05-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_fa1d7ab8_ee8e_485a_b345_34e99e339b60"></a><div style="padding-top:1.0px;border-top:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:DocumentType" id="Narr_FydSm3J_EUqsYAb5ppQ-4A"><b style="font-size:10pt;font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION&#160;13 OR 15(D) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_glU3weE3y0CmbnjtccoVhg"><b style="font-size:10pt;font-weight:bold;">May 23, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:20pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:EntityRegistrantName" id="Narr_9pFVbmgw60265wo4OSVQag"><b style="font-weight:bold;">Marinus Pharmaceuticals, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(Exact name of registrant as specified in its charter)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p><a id="_4278ba5b_f41e_4201_900d_53a40560b659"></a><a id="Tc_C2gGwDoBrk25FmEI6T-lwA_2_0"></a><a id="Tc_FxYzHneDik-UsIRGT4U92A_2_2"></a><a id="Tc_VwOjP97wdUu_gRxCnyBTjw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:85%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:32.25%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_BPbzQDd_QEqCRBQPmo04vw_1_0"><b style="font-size:10pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.6%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.25%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:EntityFileNumber" id="Tc_WHpPIioILU2rxwKthBU1Hw_1_2"><b style="font-size:10pt;font-weight:bold;">001-36576</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.62%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.26%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:EntityTaxIdentificationNumber" id="Tc_HPmV4EwQBEiEqp_oxL4MYw_1_4"><b style="font-size:10pt;font-weight:bold;">20-0198082</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:32.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(State or other jurisdiction of incorporation)</i></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(Commission File Number)</i></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(IRS Employer Identification No.)</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:1.19;text-align:justify;margin:0pt;">&#160;</p><a id="_ef7a7c97_9175_4073_a956_0405038ba4e1"></a><a id="Tc_fITeHIOdj0iOcqCTQ6y97w_0_0"></a><a id="Tc_8IpYLrvMI0eIB5l-fqJScQ_1_0"></a><a id="Tc_FYwfa3MeFk68xPKokyumOQ_2_0"></a><a id="Tc_Q9FGpgRq90-Gzw_dCCel1A_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:50%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">, Radnor, PA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:24.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.16%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:EntityAddressAddressLine1" id="Narr_JEtUCbHEckGyrH9tWX71HQ"><b style="font-size:10pt;font-weight:bold;">5 Radnor Corporate Center</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:EntityAddressAddressLine2" id="Narr_NiH5Z1nRR0-cQ-O0mqptLA"><b style="font-size:10pt;font-weight:bold;">Suite 500</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:EntityAddressAddressLine3" id="Narr_kidzzka-n0WBHqJchS6ujQ"><b style="font-size:10pt;font-weight:bold;">100 Matsonford Rd</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:EntityAddressCityOrTown" id="Narr_lwSoNpVdA0-fTabNiVjv6Q"><b style="font-size:10pt;font-weight:bold;">Radnor</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:EntityAddressStateOrProvince" id="Narr_ZkfOqIjrhUG1cMq2FDHAvg"><b style="font-size:10pt;font-weight:bold;">PA</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.43%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:24.4%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:EntityAddressPostalZipCode" id="Tc_saMmTIp7bUmdi6poiXVi2Q_1_2"><b style="font-size:10pt;font-weight:bold;">19087</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(Address of principal executive offices)</i></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:24.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(Zip Code)</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:10pt;">Registrant&#8217;s telephone number, including area code:&#160;</span><b style="font-size:10pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:CityAreaCode" id="Narr_ZW5IKCLIykiPyYudqGEyKQ"><b style="font-size:10pt;font-weight:bold;">484</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:LocalPhoneNumber" id="Narr_Ju0l2-K0h0qZ0Xy496_hBQ"><b style="font-size:10pt;font-weight:bold;">801-4670</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">__________________________________________________________________&#160;&#160;<br /><i style="font-style:italic;">(Former name or former address, if changed since last report.)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="_cfd2ad5f_4b82_4e1f_b63b_b414ee7f13dd"></a><a id="Tc_9979cyviwUqak02G7V0Erw_0_0"></a><a id="Tc_n1B7jZ2J6ESCQSB8_KqD0g_1_2"></a><a id="Tc_fsQDJxhMgEq_AVf78BEU1g_3_2"></a><a id="Tc_KvbZiuNry066RUQOv19mvw_5_2"></a><a id="Tc_wV5Voazp7EuSdqpVVi0EYQ_7_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></div></div></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_EcRFdrjbG06lb7vZ20H64A_1_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr><td style="vertical-align:middle;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc__20Ll9YmMEyebU3RiMww2Q_3_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr><td style="vertical-align:middle;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_vW2w55hQlkuGiTvr9F_yiQ_5_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr><td style="vertical-align:middle;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_3gb57NCSikq79qTJpmoXng_7_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 6pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><a id="_6f53b366_6055_4e0b_9ee3_4a168dba890a"></a><a id="Tc_c8v4ntoJk0ywePhLHk3LvA_1_0"></a><a id="Tc_ifZmwhAFfkGI2KEDuYuBew_1_1"></a><a id="Tc_gxywip3_MUC8MtMCcLNvyw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:89.7%;"><tr style="height:1pt;"><td style="vertical-align:top;width:34.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:20.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:34.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 2.2pt 0pt;">Title of each class</p></td><td style="vertical-align:top;width:20.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 2.2pt 0pt;">Trading Symbol(s)</p></td><td style="vertical-align:top;width:44.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 2.2pt 0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:34.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:Security12bTitle" id="Tc_KZBvJRZoZU2Ckd3HIo6O-g_2_0"><span style="font-size:10pt;">Common Stock, par value $0.001</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:20.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" name="dei:TradingSymbol" id="Tc_5A81ttITM0aPKFJh2HRxgg_2_1"><span style="font-size:10pt;">MRNS</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:44.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_bx9zvo4A_UqvmMfOgzH6yQ_2_2"><span style="font-size:10pt;">Nasdaq Global Market </span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:6pt 0pt 0pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-top:6pt;text-align:right;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Emerging growth company&#160;&#160;</span><ix:nonNumeric contextRef="Duration_5_23_2022_To_5_23_2022_UOYkjmhRdkmt2Z0xJm7aow" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_A-ELDWvvsU6ATaG24v4SaQ"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><div style="padding-bottom:1.0px;border-bottom:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:1pt;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:4pt;visibility:hidden;">&#8203;</span></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c78d465c_e524_4a3e_b363_f6e6f4f2987d"></a><a id="_9kR3WTr8E8457QQtnBDE"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Item 1.01.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Entry into a Material Definitive Agreement.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">On May 23, 2022, Marinus Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into an amendment (the &#8220;Amendment&#8221;) to its previously disclosed Credit Agreement and Guaranty dated as of May 11, 2021 with Oaktree Fund Administration, LLC, as administrative agent (the &#8220;Administrative Agent&#8221;), and the lenders party thereto (as amended by that certain Letter Agreement re: Minimum Liquidity Amount dated May 17, 2021, the &#8220;Credit Agreement&#8221;), to extend the commitment termination date for the $25.0 million of Tranche C term loan commitment (the &#8220;Tranche C Term Loan Commitment&#8221;) to December 31, 2023 and to eliminate the 0.75% commitment fee applicable to the Tranche C Term Loan Commitment. The availability of the Tranche C Term Loan Commitment remains subject to the Company&#8217;s achievement of certain financing and product development milestones and satisfaction of certain other conditions specified in the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">This description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is attached hereto as Exhibit 10.1 and is incorporated by reference herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Separately, on May 16, 2022, pursuant to the Credit Agreement, the Company also delivered to the Administrative Agent a separate notice of commitment termination with respect to the $25.0 million of Tranche D term loan commitment (the &#8220;Tranche D Term Loan Commitment&#8221;). Following the termination of the Tranche D Term Loan Commitment, the total funds available under the Credit Agreement will be $100.0 million, consisting of $75.0 million of previously drawn term loans and $25.0 million of the Tranche C Term Loan Commitment. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The description of the Credit Agreement is not complete and is qualified in its entirety by reference to the complete text of the Credit Agreement. A copy of the Credit Agreement is filed as Exhibits 10.1 and 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 17, 2021.</p><a id="_9kR3WTr8E8458RQtnJLE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Item 9.01</b><b style="font-size:10pt;font-weight:bold;">.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Financial Statements and Exhibits.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:49.5pt;text-indent:-49.5pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_9kR3WTr8E8459n"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">Exhibits</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:49.5pt;text-indent:-49.5pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:0.75pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.83%;padding:0.75pt;"><tr style="height:1pt;"><td style="vertical-align:middle;width:8.3%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.92%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:89.76%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:8.3%;margin:0pt;padding:0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit No. </b></p></td><td style="vertical-align:middle;width:1.92%;margin:0pt;padding:0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160; &#160;</b></p></td><td style="vertical-align:middle;width:89.76%;margin:0pt;padding:0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description </b></p></td></tr><tr><td style="vertical-align:top;width:8.3%;margin:0pt;padding:0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.1</p></td><td style="vertical-align:middle;width:1.92%;margin:0pt;padding:0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:89.76%;margin:0pt;padding:0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="mrns-20220523xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Agreement re: Amendment to Tranche C Commitment, dated May 23, 2022, by and among Marinus Pharmaceuticals, Inc., as Borrower, Oaktree Fund Administration, LLC, as Administrative Agent and the other lenders party thereto.</span></a></p></td></tr><tr><td style="vertical-align:middle;width:8.3%;margin:0pt;padding:0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">104</p></td><td style="vertical-align:middle;width:1.92%;margin:0pt;padding:0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:89.76%;margin:0pt;padding:0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background:#ffffff;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:12pt 0pt 12pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_08abcab4_01a3_4247_b56c_084430e303c1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:12.0pt;margin:0pt;"><span style="display:inline-block;width:216pt;"></span><b style="font-size:10pt;font-weight:bold;text-transform:uppercase;">MARINUS</b><b style="font-size:10pt;font-weight:bold;"> PHARMACEUTICALS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:12.0pt;margin:0pt;"><span style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:12.0pt;margin:0pt;"><span style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Date: May 25, 2022<span style="display:inline-block;width:136.01pt;"></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Steven Pfanstiel</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><span style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:175.34pt;">&#8203; &#8203;<span style="display:inline-block;height:0pt;width:100%;"></span></span></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"></span><span style="display:inline-block;width:144pt;"></span><span style="font-size:10pt;">Steven Pfanstiel</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"></span><span style="display:inline-block;width:144pt;"></span><span style="font-size:10pt;">Chief Financial Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "mrns-20220523x8k.htm", "description": "8-K", "secsgml_size_bytes": 48626}]
{"company-data": {"conformed-name": "MARINUS PHARMACEUTICALS, INC.", "cik": "0001267813", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36576", "film-number": "22962893"}, "business-address": {"street1": "5 RADNOR CORPORATE CENTER SUITE 500", "street2": "100 MATSONFORD RD", "city": "RADNOR", "state": "PA", "zip": "19087", "phone": "484-801-4670"}, "mail-address": {"street1": "5 RADNOR CORPORATE CENTER SUITE 500", "street2": "100 MATSONFORD RD", "city": "RADNOR", "state": "PA", "zip": "19087"}, "former-company": {"former-conformed-name": "MARINUS PHARMACEUTICALS INC", "date-changed": "20031022"}}
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
May 23, 2022
​
Marinus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
​
​
​
​
​
Delaware
001-36576
20-0198082
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
, Radnor, PA
​
​
​
​
5 Radnor Corporate Center
,
Suite 500
100 Matsonford Rd
,
Radnor
,
PA
19087
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(
484
)
801-4670
__________________________________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
​
​
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
​
Securities registered pursuant to Section 12(b) of the Act:
​
​
​
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001
MRNS
Nasdaq Global Market
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
​
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
​
​
​
​
​
Item 1.01.
Entry into a Material Definitive Agreement.
​
On May 23, 2022, Marinus Pharmaceuticals, Inc. (the "Company") entered into an amendment (the "Amendment") to its previously disclosed Credit Agreement and Guaranty dated as of May 11, 2021 with Oaktree Fund Administration, LLC, as administrative agent (the "Administrative Agent"), and the lenders party thereto (as amended by that certain Letter Agreement re: Minimum Liquidity Amount dated May 17, 2021, the "Credit Agreement"), to extend the commitment termination date for the $25.0 million of Tranche C term loan commitment (the "Tranche C Term Loan Commitment") to December 31, 2023 and to eliminate the 0.75% commitment fee applicable to the Tranche C Term Loan Commitment. The availability of the Tranche C Term Loan Commitment remains subject to the Company's achievement of certain financing and product development milestones and satisfaction of certain other conditions specified in the Credit Agreement.
​
This description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is attached hereto as Exhibit 10.1 and is incorporated by reference herein.
​
Separately, on May 16, 2022, pursuant to the Credit Agreement, the Company also delivered to the Administrative Agent a separate notice of commitment termination with respect to the $25.0 million of Tranche D term loan commitment (the "Tranche D Term Loan Commitment"). Following the termination of the Tranche D Term Loan Commitment, the total funds available under the Credit Agreement will be $100.0 million, consisting of $75.0 million of previously drawn term loans and $25.0 million of the Tranche C Term Loan Commitment.
​
The description of the Credit Agreement is not complete and is qualified in its entirety by reference to the complete text of the Credit Agreement. A copy of the Credit Agreement is filed as Exhibits 10.1 and 10.3 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 17, 2021.
​
Item 9.01
.
Financial Statements and Exhibits.
​
(d)
Exhibits
​
​
​
​
Exhibit No.
Description
10.1
​
Letter Agreement re: Amendment to Tranche C Commitment, dated May 23, 2022, by and among Marinus Pharmaceuticals, Inc., as Borrower, Oaktree Fund Administration, LLC, as Administrative Agent and the other lenders party thereto.
104
​
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
​
​
​
​
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MARINUS
PHARMACEUTICALS, INC.
​
​
Date: May 25, 2022
/s/ Steven Pfanstiel
​ ​
Steven Pfanstiel
Chief Financial Officer
​
​
​
​
​